Skip to main content

Table 3 Effectiveness In Head To Head Trials Comparing Biologic with Combination DMARD Strategies Assessed By Random Risk Ratio and Heterogeneity

From: Intensive therapy and remissions in rheumatoid arthritis: a systematic review

  Trials Random Risk Ratio (95% CI) Heterogeneity
All 6 1.06 (0.93, 1.21) I2 = 21%
Early 4 1.05 (0.88, 1.24) I2 = 40%
Established 2 1.21 (0.88, 1.68) I2 = 0%
Established First 6 Months 2 1.74 (1.14, 2.64) I2 = 0%